A New Clue Emerges How APOE4 Damages the Blood-Brain Barrier

New research identifies fibronectin as a potential link between APOE4, inflammation and blood-brain barrier dysfunction—and points toward some intriguing possibilities for prevention research.

In the years I’ve been researching the APOE4 and AD Prevention topic, I’ve often seen reference to the integrity of our blood-brain barrier (BBB). The BBB is a highly specialized vascular system that controls what passes from our circulation into the brain - both the good and the bad.

We have known for some time that APOE4 is associated with greater blood-brain barrier dysfunction. Exactly what the role of APOE4 is, and how it behaves at the blood brain barrier, remains elusive.

A fascinating new study published September 11, 2026 in Nature Aging may have identified another important piece of that puzzle: Fibronectin.

Although fibronectin isn’t exactly a household word, this study may have important implications for how we think about protecting the APOE4 brain long before cognitive symptoms appear.

What Is Fibronectin?

Fibronectin is a normal and essential protein in the extracellular matrix—essentially part of the structural environment surrounding our cells. It plays important roles in wound healing, cell adhesion, tissue repair and communication between cells.

The problem appears to be too much fibronectin in the wrong place.

APOE4 Astrocytes Produce More Fibronectin

The researchers used genetically matched human astrocytes carrying either APOE3/3 or APOE4/4.

The difference was striking.

APOE4/4 astrocytes showed increased fibronectin expression and abnormal fibronectin deposits. In human brain data, astrocytes also showed the strongest APOE4-associated increase in FN1, the gene encoding fibronectin.

The researchers then looked at aged APOE3 and APOE4 knock-in mice.

The APOE4 mice had approximately 99% higher brain fibronectin levels than APOE3 mice.

Importantly, this occurred in an APOE4 model without requiring overt Alzheimer’s pathology.

That suggests that APOE4 itself may help create a vascular environment favorable to fibronectin accumulation.

Amyloid and Inflammation Make It Worse

APOE4 wasn’t acting alone.

The researchers found that amyloid-beta 42 and inflammatory signaling also increased fibronectin production.

TNF, an inflammatory cytokine, activated NF-κB signaling in astrocytes and increased fibronectin.

This results in an interesting convergence:

APOE4 + amyloid + inflammation → increased fibronectin

And the location matters.

The fibronectin accumulated around the blood vessels at astrocytic endfeet—the very interface where communication between brain cells and the vascular system helps maintain the BBB.

Fibronectin Wasn’t Just a Marker

This is perhaps the most important part of the study. It would be easy to assume that fibronectin simply accumulates because the brain or blood vessels are already damaged.

The researchers tested that possibility.

When they experimentally increased fibronectin in astroglia, fibronectin itself was sufficient to cause blood-brain barrier leakage.

Conversely, reducing fibronectin improved BBB function in experimental models.

That moves fibronectin from being merely an interesting biomarker toward being a possible mediator of the damage.

How Does Fibronectin Damage the BBB?

The mechanism is fascinating.

Excess fibronectin appears to disrupt the normal communication between astrocytes and the blood vessels they help protect. It interferes with important signaling pathways that help maintain healthy blood vessels and an intact blood-brain barrier.

Put simply:

APOE4 + amyloid + inflammation
↓
Too much fibronectin around brain blood vessels
↓
Normal communication between astrocytes and blood vessels is disrupted
↓
The blood-brain barrier becomes more vulnerable and leaky

Importantly, this pathway offers researchers several possible targets for preventing or reversing the damage.

There May Be More Than One APOE4 Pathway to BBB Damage

This is where the new discovery becomes even more interesting.

Fibronectin isn’t the first mechanism researchers have identified linking APOE4 to BBB breakdown.

More than a decade ago, researchers identified another way APOE4 may damage the blood-brain barrier. APOE4 can trigger inflammatory activity in cells surrounding brain blood vessels, leading to the breakdown of proteins that help keep the barrier strong.

Put simply:

APOE4
↓
Increased inflammation around brain blood vessels
↓
Breakdown of the blood-brain barrier
↓
Increased leakage

That pathway is particularly interesting because vascular abnormalities appeared before neuronal dysfunction in experimental APOE4 models.

We may therefore be looking at at least two interacting mechanisms:

Pericytes:
APOE4 → CypA → NF-κB → MMP-9 → BBB degradation

Astrocytes:
APOE4 / amyloid / inflammation → fibronectin → integrin/FAK → disrupted growth-factor signaling → BBB dysfunction

Different cells. Different pathways.

Same vulnerable blood-brain barrier.

And inflammation—particularly NF-κB signaling—may connect portions of the two.

An Unexpected Connection to mTOR

This is where another piece of research caught my attention.

The new fibronectin study did not test rapamycin, so what follows is a mechanistic possibility—not evidence that rapamycin prevents this newly identified APOE4 pathway.

However, there is older research showing that mTOR signaling regulates extracellular-matrix production, including fibronectin.

In fibroblast experiments, activation of the Akt/mTOR pathway increased production of extracellular-matrix proteins, while inhibiting mTOR with rapamycin reduced fibronectin production and secretion.

Other experimental studies have similarly found that rapamycin can suppress TGF-β-induced fibronectin production.

Why is that particularly interesting in APOE4?

Because rapamycin has already been tested in APOE4 mice.

In a published APOE4 mouse study, rapamycin restored blood-brain barrier integrity and cerebral blood flow and normalized vascular cyclophilin A levels. The treated animals also showed improvements in brain glucose metabolism and early learning deficits.

So we already have evidence in an APOE4 animal model connecting rapamycin with:

↓ abnormal CypA signaling

and

↑ BBB integrity

Separately, we have experimental evidence from other tissues showing:

mTOR inhibition → ↓ fibronectin production

Now we have a new APOE4 study showing:

↑ fibronectin → BBB dysfunction

The missing experiment is obvious—and important:

Does mTOR inhibition reduce the abnormal astrocytic/perivascular fibronectin produced in an APOE4 brain?

As far as I can determine, we don’t yet know.

That is very different from saying rapamycin has been proven to prevent this pathway. It hasn’t.

But mechanistically, it’s a question worth asking.

Can We Lower Brain Fibronectin Today?

This is where I think caution is warranted.

There is currently no established treatment shown to selectively lower pathological perivascular fibronectin in the human APOE4 brain.

What the research does reinforce, however, is the potential importance of controlling the biological environment that appears to promote abnormal fibronectin deposition.

In the new study, inflammation increased fibronectin.

Amyloid increased it.

APOE4 increased it.

That gives me another reason to pay attention to metabolic and vascular health, chronic inflammatory burden, exercise, sleep and the other modifiable factors that influence the environment in which the aging brain operates—even though we cannot yet say that any particular lifestyle intervention lowers brain fibronectin.

My Bigger Takeaway

For me, this paper reinforces something I’ve increasingly come to believe about APOE4 and Alzheimer’s prevention:

Researchers are identifying the downstream consequences of APOE4—and those may be much more modifiable than the gene itself.

---

Research discussed

Bhattarai P, Yilmaz E, Cakir EÖ, et al. Fibronectin mediates APOE4-driven blood–brain barrier dysfunction in Alzheimer’s disease. Nature Aging. Published September 11, 2026.

Bell RD, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012.

Lin AL, et al. Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease. Journal of Cerebral Blood Flow & Metabolism. 2017.